Zhu Z, Zhang J, Xu Z, Wang Q, Qi Y, Yang L
Int J Equity Health. 2025; 24(1):36.
PMID: 39905408
PMC: 11796270.
DOI: 10.1186/s12939-025-02390-w.
Michaeli D, Michaeli T
Pharmacoeconomics. 2024; .
PMID: 39739243
DOI: 10.1007/s40273-024-01448-x.
Ou W, Hsu K, Tseng J, Lee P, Chen K, Huang Y
Ther Adv Med Oncol. 2024; 16:17588359241290718.
PMID: 39483140
PMC: 11526195.
DOI: 10.1177/17588359241290718.
Conti R, McCue S, Dockter T, Gunn H, Dusetzina S, Bennett A
medRxiv. 2024; .
PMID: 39371185
PMC: 11451638.
DOI: 10.1101/2024.09.13.24311098.
Levaggi L, Levaggi R
Pharmacy (Basel). 2024; 12(2).
PMID: 38525730
PMC: 10961771.
DOI: 10.3390/pharmacy12020050.
Pricing strategy research in the dual-channel pharmaceutical supply chain considering service.
Lu Q, Liu Q, Wang Y, Guan M, Zhou Z, Wu Y
Front Public Health. 2024; 12:1265171.
PMID: 38439763
PMC: 10909984.
DOI: 10.3389/fpubh.2024.1265171.
Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS.
Yoon N, Na Y, Lee J, Song I, Lee E, Park M
J Cancer Res Clin Oncol. 2024; 150(3):113.
PMID: 38436796
PMC: 10912263.
DOI: 10.1007/s00432-023-05587-0.
Pairwise association of key lifestyle factors and risk of solid cancers - A prospective pooled multi-cohort register study.
Roos E, Heikkinen S, Seppa K, Pietilainen O, Ryynanen H, Laaksonen M
Prev Med Rep. 2024; 38:102607.
PMID: 38298822
PMC: 10828451.
DOI: 10.1016/j.pmedr.2024.102607.
Price negotiation and pricing of anticancer drugs in China: An observational study.
Zhou J, Lan T, Lu H, Pan J
PLoS Med. 2024; 21(1):e1004332.
PMID: 38166148
PMC: 10793910.
DOI: 10.1371/journal.pmed.1004332.
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.
Weth F, Hoggarth G, Weth A, Paterson E, White M, Tan S
Br J Cancer. 2023; 130(5):703-715.
PMID: 38012383
PMC: 10912636.
DOI: 10.1038/s41416-023-02502-9.
Outcomes of the 340B Drug Pricing Program: A Scoping Review.
Knox R, Wang J, Feldman W, Kesselheim A, Sarpatwari A
JAMA Health Forum. 2023; 4(11):e233716.
PMID: 37991784
PMC: 10665972.
DOI: 10.1001/jamahealthforum.2023.3716.
Trends in medical care utilization in patients with cancer: An analysis of real-world data in a tertiary hospital in Korea, 2014-2019.
Won J, Chung T, Lee J, Yoon S, Jeon Y, Lee H
Cancer Med. 2023; 12(22):21022-21031.
PMID: 37902239
PMC: 10709731.
DOI: 10.1002/cam4.6660.
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
Michaeli D, Michaeli T
Pharmacoeconomics. 2023; 42(1):117-131.
PMID: 37855850
PMC: 10791980.
DOI: 10.1007/s40273-023-01320-4.
Challenges and Strategies for Improving Access to Cancer Drugs in Malaysia: Summary of Opinions Expressed at the 2nd MACR International Scientific Conference 2022.
Tan S, Poh W, Yong A, Chua E, Ooi D, Mahmud R
Cancer Manag Res. 2023; 15:851-862.
PMID: 37636030
PMC: 10457461.
DOI: 10.2147/CMAR.S420890.
Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?.
Chauca Strand G, Johansson N, Jakobsson N, Bonander C, Svensson M
Clin Drug Investig. 2023; 43(8):621-633.
PMID: 37505421
PMC: 10480259.
DOI: 10.1007/s40261-023-01285-4.
Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.
Wang T, Li Y, Zheng X
BMC Health Serv Res. 2023; 23(1):691.
PMID: 37365540
PMC: 10294391.
DOI: 10.1186/s12913-023-09727-7.
The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance.
Horny M, Yabroff K, Filson C, Zheng Z, Ekwueme D, Richards T
Cancer. 2023; 129(20):3252-3262.
PMID: 37329254
PMC: 10527879.
DOI: 10.1002/cncr.34905.
Price, Availability and Affordability of Anti-Cancer Medicines in Addis Ababa, Ethiopia.
Alemu B, Hailemariam F
Risk Manag Healthc Policy. 2023; 15:2421-2433.
PMID: 36601534
PMC: 9807119.
DOI: 10.2147/RMHP.S395456.
Cancer-related costs, the resulting financial impact and coping strategies among cancer survivors living in a setting with a pluralistic health system: a qualitative study.
Fnu N, Kuan W, Kong Y, Bustamam R, Wong L, Subramaniam S
Ecancermedicalscience. 2022; 16:1449.
PMID: 36405936
PMC: 9666287.
DOI: 10.3332/ecancer.2022.1449.
Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration-approved solid tumor therapies, 1995-2021.
Alabaku O, Laffey T, Suh K, Li M
J Manag Care Spec Pharm. 2022; 28(11):1219-1223.
PMID: 36282934
PMC: 10372986.
DOI: 10.18553/jmcp.2022.28.11.1219.
